Premium
Single‐strain regression analysis evaluating disc potencies of flumequine and enrofloxacin for testing Aeromonas sobria and Vibrio anguillarum
Author(s) -
Kronvall Göran,
Baron Sandrine,
Larvor Emeline,
Rudas–Villarreal Casandra,
Hobson Jonathan,
Smith Peter
Publication year - 2019
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12972
Subject(s) - flumequine , enrofloxacin , vibrio anguillarum , aeromonas , antimicrobial , vibrio , microbiology and biotechnology , oxolinic acid , biology , antibiotics , ciprofloxacin , bacteria , nalidixic acid , genetics
Two quite different disc contents are used for antimicrobial susceptibility testing of two fluoroquinolone drugs, flumequine and enrofloxacin, in the disc diffusion test, 30 and 5 µg, respectively. Using the SRA method, single‐strain regression analysis, we studied the impact of disc content when testing two relevant bacterial species, Aeromonas sobria and Vibrio anguillarum . There were no major differences between the antimicrobial regression lines for the two species. Wild‐type strains produced acceptable zones of inhibition over a wide range of disc contents. The flumequine 30 µg disc should be lowered in its drug content. No rational reasons for choosing so different disc contents for the two antimicrobials were apparent. At present, the choice of disc content for new antimicrobials are outside the realm of clinical microbiologists. It is recommended that reference authorities, such as EUCAST, CLSI and USCAST, are consulted for the choice of disc contents in the future.